NYSE:PFE

Pfizer Inc (PFE)

25.01
+0.10 (0.40%)
as of Jul 31, 2026, 8:00:00 pm Market Open.
581 watching
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
WEAK BUY
Starting to look good at $26.
DON'T BUY
Great company. Could drop further.
BUY ON WEAKNESS
Good long term track record. Good management. Would like at a lower level.
BUY
Likes the drug sector.
BUY
Sector has been hit hard. At a good level. Prefers Pfizer over Merck.
DON'T BUY
DON'T BUY
Maney that went in as a defensive move is now leaving. Valuation in the sector got too high.
BUY
Excellent company. Should meet their growth potential this year. Great product lines.
WEAK BUY
Company has been doing well. Revenues growing @ 10%, earnings @ 20%. Trading at 19 X. Great long term.
DON'T BUY
Expensive.
TOP PICK
(Was a top pick on Mar 23 no change) A fan of pharmaceuticals and thinks this is the best. Goor R&D and sales.
DON'T BUY
Great com;pany. Valuation is too high.
STRONG BUY
Great product line/sales force. Good price.
DON'T BUY
Has a good pipeline. Should improve towards the end of the year.
DON'T BUY
Great pipeline of products, but has trouble breaking through the $44 level.
Showing 811 to 825 of 885 entries